These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 19309330)

  • 1. Comparison of symptomatic versus functional changes in children and adolescents with ADHD during randomized, double-blind treatment with psychostimulants, atomoxetine, or placebo.
    Buitelaar JK; Wilens TE; Zhang S; Ning Y; Feldman PD
    J Child Psychol Psychiatry; 2009 Mar; 50(3):335-42. PubMed ID: 19309330
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transition from methylphenidate or amphetamine to atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder--a preliminary tolerability and efficacy study.
    Quintana H; Cherlin EA; Duesenberg DA; Bangs ME; Ramsey JL; Feldman PD; Allen AJ; Kelsey DK
    Clin Ther; 2007 Jun; 29(6):1168-77. PubMed ID: 17692731
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Atomoxetine hydrochloride in the treatment of children and adolescents with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder: A placebo-controlled Italian study.
    Dell'Agnello G; Maschietto D; Bravaccio C; Calamoneri F; Masi G; Curatolo P; Besana D; Mancini F; Rossi A; Poole L; Escobar R; Zuddas A;
    Eur Neuropsychopharmacol; 2009 Nov; 19(11):822-34. PubMed ID: 19716683
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of atomoxetine in adolescents with attention-deficit/hyperactivity disorder and major depression.
    ; Bangs ME; Emslie GJ; Spencer TJ; Ramsey JL; Carlson C; Bartky EJ; Busner J; Duesenberg DA; Harshawat P; Kaplan SL; Quintana H; Allen AJ; Sumner CR
    J Child Adolesc Psychopharmacol; 2007 Aug; 17(4):407-20. PubMed ID: 17822337
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Atomoxetine improved attention in children and adolescents with attention-deficit/hyperactivity disorder and dyslexia in a 16 week, acute, randomized, double-blind trial.
    Wietecha L; Williams D; Shaywitz S; Shaywitz B; Hooper SR; Wigal SB; Dunn D; McBurnett K
    J Child Adolesc Psychopharmacol; 2013 Nov; 23(9):605-13. PubMed ID: 24206099
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of modafinil film-coated tablets in children and adolescents with attention-deficit/hyperactivity disorder: results of a randomized, double-blind, placebo-controlled, flexible-dose study.
    Biederman J; Swanson JM; Wigal SB; Kratochvil CJ; Boellner SW; Earl CQ; Jiang J; Greenhill L
    Pediatrics; 2005 Dec; 116(6):e777-84. PubMed ID: 16322134
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Atomoxetine treatment in children and adolescents with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder.
    Newcorn JH; Spencer TJ; Biederman J; Milton DR; Michelson D
    J Am Acad Child Adolesc Psychiatry; 2005 Mar; 44(3):240-8. PubMed ID: 15725968
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modafinil improves symptoms of attention-deficit/hyperactivity disorder across subtypes in children and adolescents.
    Biederman J; Pliszka SR
    J Pediatr; 2008 Mar; 152(3):394-9. PubMed ID: 18280848
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Does placebo response differ between objective and subjective measures in children with attention-deficit/hyperactivity disorder?
    Sumner CR; Haynes VS; Teicher MH; Newcorn JH
    Postgrad Med; 2010 Sep; 122(5):52-61. PubMed ID: 20861588
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Atomoxetine treatment in children and adolescents with ADHD and comorbid tic disorders.
    Allen AJ; Kurlan RM; Gilbert DL; Coffey BJ; Linder SL; Lewis DW; Winner PK; Dunn DW; Dure LS; Sallee FR; Milton DR; Mintz MI; Ricardi RK; Erenberg G; Layton LL; Feldman PD; Kelsey DK; Spencer TJ
    Neurology; 2005 Dec; 65(12):1941-9. PubMed ID: 16380617
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Atomoxetine treatment in adults with attention-deficit/hyperactivity disorder and comorbid social anxiety disorder.
    Adler LA; Liebowitz M; Kronenberger W; Qiao M; Rubin R; Hollandbeck M; Deldar A; Schuh K; Durell T
    Depress Anxiety; 2009; 26(3):212-21. PubMed ID: 19194995
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Core ADHD symptom improvement with atomoxetine versus methylphenidate: a direct comparison meta-analysis.
    Hazell PL; Kohn MR; Dickson R; Walton RJ; Granger RE; Wyk GW
    J Atten Disord; 2011 Nov; 15(8):674-83. PubMed ID: 20837981
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of atomoxetine for first-line treatment of newly diagnosed, treatment-naïve children and adolescents with attention deficit/hyperactivity disorder.
    Montoya A; Hervas A; Cardo E; Artigas J; Mardomingo MJ; Alda JA; Gastaminza X; García-Polavieja MJ; Gilaberte I; Escobar R
    Curr Med Res Opin; 2009 Nov; 25(11):2745-54. PubMed ID: 19785510
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of parent and teacher reports of attention-deficit/hyperactivity disorder symptoms from two placebo-controlled studies of atomoxetine in children.
    Biederman J; Gao H; Rogers AK; Spencer TJ
    Biol Psychiatry; 2006 Nov; 60(10):1106-10. PubMed ID: 16806096
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A comparison of the efficacy of medications for adult attention-deficit/hyperactivity disorder using meta-analysis of effect sizes.
    Faraone SV; Glatt SJ
    J Clin Psychiatry; 2010 Jun; 71(6):754-63. PubMed ID: 20051220
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Atomoxetine versus methylphenidate in paediatric outpatients with attention deficit hyperactivity disorder: a randomized, double-blind comparison trial.
    Wang Y; Zheng Y; Du Y; Song DH; Shin YJ; Cho SC; Kim BN; Ahn DH; Marquez-Caraveo ME; Gao H; Williams DW; Levine LR
    Aust N Z J Psychiatry; 2007 Mar; 41(3):222-30. PubMed ID: 17464703
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Atomoxetine for the treatment of attention-deficit/hyperactivity disorder and oppositional defiant disorder.
    Bangs ME; Hazell P; Danckaerts M; Hoare P; Coghill DR; Wehmeier PM; Williams DW; Moore RJ; Levine L;
    Pediatrics; 2008 Feb; 121(2):e314-20. PubMed ID: 18245404
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term atomoxetine treatment in adolescents with attention-deficit/hyperactivity disorder.
    Wilens TE; Newcorn JH; Kratochvil CJ; Gao H; Thomason CK; Rogers AK; Feldman PD; Levine LR
    J Pediatr; 2006 Jul; 149(1):112-9. PubMed ID: 16860138
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The reliability and validity of self- and investigator ratings of ADHD in adults.
    Adler LA; Faraone SV; Spencer TJ; Michelson D; Reimherr FW; Glatt SJ; Marchant BK; Biederman J
    J Atten Disord; 2008 May; 11(6):711-9. PubMed ID: 18025250
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Atomoxetine treatment of adults with ADHD and comorbid alcohol use disorders.
    Wilens TE; Adler LA; Weiss MD; Michelson D; Ramsey JL; Moore RJ; Renard D; Brady KT; Trzepacz PT; Schuh LM; Ahrbecker LM; Levine LR;
    Drug Alcohol Depend; 2008 Jul; 96(1-2):145-54. PubMed ID: 18403134
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.